Hong Kong Stock Market Fluctuation | Pharmaron Health-B (02617.HK) opens over 8%, approval obtained for II phase clinical trial of Enzalutamide in combination with new endocrine therapy for post-treatment progression in mCRPC.

According to the Wisdom Financial APP, China Medical System Holdings Limited (02617.HK) opened more than 8% higher, rose by 8.12% as of the time of publishing, at 43.92 Hong Kong dollars, with a trading volume of 2.1082 million Hong Kong dollars.